Lantheus Holdings (LNTH) Non-Current Debt (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Non-Current Debt came in at $569.6 million in Q1 2026, up 0.62% year-on-year from $566.1 million in Q1 2025, and little changed on a QoQ basis from $568.7 million in Q4 2025.
Lantheus Holdings (LNTH) Non-Current Debt (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Non-Current Debt data on file, last reported at $569.6 million in Q1 2026.
- On a quarterly basis, Non-Current Debt rose 0.62% year-over-year to $569.6 million in Q1 2026; TTM through Mar 2026 was $569.6 million, a 0.62% increase from a year earlier, with the FY2025 full-year figure at $568.7 million, up 0.6% from the prior year.
- Non-Current Debt for Q1 2026 stood at $569.6 million, roughly flat from $568.7 million in the prior quarter.
- Over the last five years, Non-Current Debt for LNTH reached as high as $569.6 million in Q1 2026 and fell as low as $613000.0 in Q3 2024.
- Historically, Non-Current Debt has averaged $458.6 million across 5 years, with a median of $561.7 million in 2023.
- Across the five-year window, Non-Current Debt sank 99.89% in 2024 and soared 92548.78% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $557.7 million in 2022, then climbed by 0.71% to $561.7 million in 2023, then increased by 0.64% to $565.3 million in 2024, then grew by 0.6% to $568.7 million in 2025, then grew by 0.16% to $569.6 million in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $569.6 million in Q1 2026, $568.7 million in Q4 2025, and $567.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 569.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 569.60 Mn |
| Dec 31, 2025 | 568.68 Mn |
| Sep 30, 2025 | 567.94 Mn |
| Jun 30, 2025 | 566.85 Mn |
| Mar 31, 2025 | 566.10 Mn |
| Dec 31, 2024 | 565.28 Mn |
| Sep 30, 2024 | 613,000.00 |
| Jun 30, 2024 | 563.19 Mn |
| Mar 31, 2024 | 562.47 Mn |
| Dec 31, 2023 | 561.67 Mn |
| Sep 30, 2023 | 560.58 Mn |
| Jun 30, 2023 | 559.24 Mn |
| Mar 31, 2023 | 558.54 Mn |
| Dec 31, 2022 | 557.71 Mn |
| Sep 30, 2022 | 152.06 Mn |
| Jun 30, 2022 | 155.66 Mn |
| Mar 31, 2022 | 159.37 Mn |
| Dec 31, 2021 | 163.12 Mn |
| Sep 30, 2021 | 166.74 Mn |
| Jun 30, 2021 | 169.25 Mn |